Cytogenetics and long-term survival of pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma

Disclosures: AB, LG, and VI have no conflict of interest disclosures; MAD has received honoraria from Celgene and Ortho Biotech; KGW has consulted for and received honoraria from Celgene, Janssen, and Onyx; KWS has participated in advisory boards and received honoraria and research funding from Celgene and Janssen; MD has consulted for Celgene and Janssen-Cilag; LK has participated in expert board committees for Celgene and Sandoz and received honoraria from Celgene and Janssen; HG has participated in advisory boards and speakers bureau and received honoraria research funding from Celgene; PM has consulted for Celgene; AO has participated in advisory boards and received honoraria from Celgene; MC has consulted for and received honoraria from Janssen, Celgene, Millennium, and Bristol-Myers Squibb; AA has participated in advisory boards for Celgene and Janssen-Cilag and received research funding from Celgene, Jansen-Cilag, and Amgen; JML has received research funding from Celgene and Novartis and honoraria from Celgene, Novartis, Bristol-Myers Squibb, and Janssen; CC has consulted for and received research funding and honoraria from Celgene; AS has received research funding from Celgene; SK has participated in advisory boards and received honoraria and research funding from Celgene; NJB has received research funding and honoraria from Celgene; CR has participated in advisory boards and received honoraria and travel support from Celgene and Janssen; JFSM has consulted for Millennium, Celgene, Novartis, Onyx, Bristol-Myers Squibb and Merck; XY, KH, LS, CJ, and MHZ are employed by and have equity ownership with Celgene.

Contributions: MD, PM, AA, XY, KH, LS, CJ, MZ, JSM contributed to the conception of the work; MD, XY, KH, LS, CJ, MZ, JSM contributed to the design of the work; MD, KW, KS, MD, LK, HG, PM, AB, AO, LG, MC, VI, AA, JML, CC, AS, SK, NB, CR, XY, KH, LS, CJ, MZ, JSM contributed to the acquisition, analysis, or interpretation of data for the work. MD, KW, KS, MD, LK, HG, PM, AB, AO, LG, MC, VI, AA, JML, CC, AS, SK, NB, CR, XY, KH, LS, CJ, MZ, JSM contributed to revising the manuscript critically for important intellectual content and approved the final version of the manuscript.